DAWN

6.45

4.59% -0.31

Handel nachbörslich: 6.36 -0.09 -1.40%

Day One Biopharmaceuticals Inc (DAWN)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$6.76

Offen:

$6.76

24-Stunden-Volumen:

1.34M

Relative Volume:

1.10

Marktkapitalisierung:

$803.74M

Einnahmen:

Nettoeinkommen (Verlust:

$-167.48M

KGV:

-3.3077

EPS:

-1.95

Netto-Cashflow:

$-197.47M

1W Leistung:

-18.66%

1M Leistung:

-11.28%

6M Leistung:

-60.65%

1J Leistung:

-60.62%

1-Tages-Spanne:

$6.35

$6.91

1-Wochen-Bereich:

$6.26

$7.955

52-Wochen-Spanne:

$6.26

$17.14

Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile

Firmenname

Day One Biopharmaceuticals Inc

Sektor

Healthcare (1153)

Branche

Biotechnology (676)

Telefon

650 484-0899

Adresse

2000 SIERRA POINT PARKWAY, SUITE 501, BRISBANE

Mitarbeiter

181

Twitter

Nächster Verdiensttermin

Neueste SEC-Einreichungen

DAWN's Discussions on Twitter

Vergleichen Sie DAWN mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
DAWN Day One Biopharmaceuticals Inc	6.45	803.74M	0	-167.48M	-197.47M	-1.95
VRTX Vertex Pharmaceuticals Inc	424.99	128.84B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	527.78	65.38B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	549.65	39.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.15	33.82B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	231.99	27.60B	3.81B	-644.79M	-669.77M	-6.24

Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-10-09	Bestätigt	Needham	Buy
2024-08-01	Hochstufung	BofA Securities	Underperform → Buy
2024-04-24	Bestätigt	Needham	Buy
2023-04-25	Herabstufung	BofA Securities	Buy → Underperform
2023-02-08	Eingeleitet	CapitalOne	Overweight
2023-02-03	Eingeleitet	Oppenheimer	Perform
2022-12-15	Eingeleitet	H.C. Wainwright	Buy
2022-12-14	Eingeleitet	Needham	Buy
2022-12-05	Eingeleitet	Goldman	Buy
2022-12-01	Eingeleitet	BofA Securities	Buy

Alle ansehen

Day One Biopharmaceuticals Inc Aktie (DAWN) Neueste Nachrichten

08:13 AM

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Purchased by Dimensional Fund Advisors LP - Defense World

08:13 AM

04:15 AM

Research Analysts Issue Forecasts for DAWN Q2 Earnings - Defense World

04:15 AM

02:37 AM

Needham & Company LLC Cuts Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $27.00 - Defense World

02:37 AM

02:09 AM

Research Analysts Set Expectations for DAWN Q2 Earnings - Defense World

02:09 AM

May 09, 2025

Is Day One Biopharmaceuticals, Inc. (DAWN) the Low Risk High Reward Stock Set to Triple by 2030? - Insider Monkey

May 09, 2025

Analysts Issue Forecasts for DAWN Q1 Earnings - Defense World

May 09, 2025

10 Low Risk High Reward Stocks Set to Triple by 2030 - Insider Monkey

May 09, 2025

May 08, 2025

Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Up After Earnings Beat - Defense World

May 08, 2025

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Sold by Mariner LLC - Defense World

May 08, 2025

Day one biopharmaceuticals highlights OJEMDA revenue growth and pipeline progress in Q1 2025 - MSN

May 08, 2025

Day One Biopharmaceuticals (NASDAQ:DAWN) Reaches New 12-Month Low Following Analyst Downgrade - Defense World

May 08, 2025

May 07, 2025

Day One Biopharma’s Earnings Call Highlights Growth - TipRanks

May 07, 2025

Day One Biopharmaceuticals (DAWN) Target Price Adjusted to $26 | DAWN Stock News - GuruFocus

May 07, 2025

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q1 2025 Earnings Call Transcript - Insider Monkey

May 07, 2025

MetLife Investment Management LLC Raises Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World

May 07, 2025

Day One Biopharmaceuticals earnings beat by $0.07, revenue fell short of estimates - Investing.com Canada

May 07, 2025

Day One Biopharmaceuticals Reports Strong Q1 2025 Results - TipRanks

May 07, 2025